U.S. markets closed
  • S&P 500

    4,119.21
    +42.61 (+1.05%)
     
  • Dow 30

    34,092.96
    +6.92 (+0.02%)
     
  • Nasdaq

    11,816.32
    +231.77 (+2.00%)
     
  • Russell 2000

    1,960.81
    +28.87 (+1.49%)
     
  • Crude Oil

    76.70
    -2.17 (-2.75%)
     
  • Gold

    1,950.70
    +21.20 (+1.10%)
     
  • Silver

    24.08
    +0.24 (+1.02%)
     
  • EUR/USD

    1.0991
    +0.0125 (+1.15%)
     
  • 10-Yr Bond

    3.3970
    -0.1320 (-3.74%)
     
  • dólar/libra

    1.2373
    +0.0057 (+0.46%)
     
  • yen/dólar

    128.9260
    -1.1420 (-0.88%)
     
  • BTC-USD

    23,700.76
    +742.81 (+3.24%)
     
  • CMC Crypto 200

    538.70
    +296.03 (+121.98%)
     
  • FTSE 100

    7,761.11
    -10.59 (-0.14%)
     
  • Nikkei 225

    27,346.88
    +19.77 (+0.07%)
     

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc.

IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at three upcoming healthcare conferences.

Jefferies Global Healthcare Conference
Date: November 15 – 17, 2022
Location: The Waldorf Hilton, London, UK

Piper Sandler Healthcare Conference
Date: November 29 – December 1, 2022
Location: Lotte New York Palace, New York, NY
Fireside Chat: November 30, 2022, at 1:30 pm ET in Holmes 2 (4th Floor)

LifeSci Partners Corporate Access Event
Date: January 9 – 11, 2023
Location: Beacon Grand Hotel, San Francisco, CA

Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com